AI Portfolio Summary
In 2025 Q4, Siren, L.L.C. maintained a portfolio of 141 distinct positions. The most significant new addition to the portfolio was Olema Pharmaceutical, which now represents 2.46% of the total fund value. They heavily accumulated shares in Scholar Rock Holding, increasing their position by 17.0%. The fund also reduced its exposure to Arrowhead Pharmaceut by 43.8%.
Total Positions
141
Quarter
2025 Q4
Top Holding
SRRK (14.2%)
Top 10 Concentration
46.3%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 141
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
SRRK
Scholar Rock Ho...
|
Healthcare | 14.22% | 13.48% |
#1
Prev: #1
|
8.0 | 1,575,008 | 17.0% |
P
S
|
10,825,013 | $476,841,823 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KYMR
Kymera Therapeu...
|
Healthcare | 7.63% | 7.59% |
#2
Prev: #2
|
5.1 | -141,320 | -4.1% |
P
S
|
3,286,830 | $255,748,242 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ONC
BeOne Medicines...
|
Healthcare | 4.53% | 6.57% |
#3
Prev: #3
|
3.3 | 7,010 | 1.4% |
P
S
|
500,000 | $151,905,000 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EWTX
Edgewise Therap...
|
Healthcare | 3.35% | 2.47% |
#4
4
Prev: #8
|
3.8 | 632,891 | 16.2% |
P
S
|
4,529,990 | $112,411,702 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RVMD
Revolution Medi...
|
Healthcare | 3.17% | 1.91% |
#5
12
Prev: #17
|
4.3 | 291,355 | 27.9% |
P
S
|
1,335,075 | $106,338,724 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CNTA
Centessa Pharma...
|
Healthcare | 3.00% | 3.06% |
#6
Prev: #6
|
3.7 | 800,000 | 24.8% |
P
S
|
4,027,517 | $100,728,200 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ARWR
Arrowhead Pharm...
|
Healthcare | 2.97% | 3.60% |
#7
3
Prev: #4
|
1.2 | -1,169,404 | -43.8% |
P
S
|
1,500,476 | $99,616,602 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BCAX
Bicara Therapeu...
|
Healthcare | 2.62% | 3.22% |
#8
3
Prev: #5
|
2.0 | no change | no change |
P
S
|
5,216,969 | $87,801,588 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OLMA
Olema Pharmaceu...
|
Healthcare | 2.46% | — |
#9
Prev: #—
|
4.5 | 3,300,700 | no change |
NEW
|
3,300,700 | $82,517,500 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IRON
Disc Medicine I...
|
Healthcare | 2.34% | 2.36% |
#10
1
Prev: #9
|
2.9 | 75,000 | 8.2% |
P
S
|
988,401 | $78,488,923 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GPCR
Structure Thera...
|
Healthcare | 2.24% | 1.12% |
#11
17
Prev: #28
|
2.9 | 51,887 | 5.1% |
P
S
|
1,078,698 | $75,023,446 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TNGX
Tango Therapeut...
|
Healthcare | 2.16% | 1.93% |
#12
4
Prev: #16
|
3.4 | 2,282,186 | 38.8% |
P
S
|
8,165,374 | $72,345,214 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RCUS
Arcus Bioscienc...
|
Healthcare | 2.14% | 1.55% |
#13
9
Prev: #22
|
1.4 | 95,000 | 3.3% |
P
S
|
3,007,077 | $71,658,645 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
STOK
Stoke Therapeut...
|
Healthcare | 2.13% | 2.07% |
#14
1
Prev: #13
|
1.9 | no change | no change |
P
S
|
2,247,347 | $71,330,794 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CRNX
Crinetics Pharm...
|
Healthcare | 2.09% | 2.75% |
#15
8
Prev: #7
|
1.3 | -180,975 | -10.7% |
P
S
|
1,507,636 | $70,180,456 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DYN
Dyne Therapeuti...
|
Healthcare | 2.04% | 2.34% |
#16
6
Prev: #10
|
0.8 | -1,226,233 | -25.9% |
P
S
|
3,502,941 | $68,517,526 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
APLS
Apellis Pharmac...
|
Healthcare | 1.93% | 2.28% |
#17
6
Prev: #11
|
1.8 | no change | no change |
P
S
|
2,578,396 | $64,769,308 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
COGT
Cogent Bioscien...
|
Healthcare | 1.73% | 0.97% |
#18
13
Prev: #31
|
1.2 | -95,000 | -5.5% |
P
S
|
1,629,279 | $57,871,990 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SEPN
Septerna Inc
|
Healthcare | 1.66% | 1.62% |
#19
2
Prev: #21
|
1.2 | -202,514 | -9.2% |
P
S
|
2,000,000 | $55,760,000 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TSHA
Taysha Gene The...
|
Healthcare | 1.66% | 1.41% |
#20
3
Prev: #23
|
1.2 | -884,824 | -8.0% |
P
S
|
10,129,913 | $55,714,522 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RYTM
Rhythm Pharmace...
|
Healthcare | 1.60% | 1.98% |
#21
6
Prev: #15
|
1.6 | no change | no change |
P
S
|
499,975 | $53,517,324 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ASND
Ascendis Pharma...
|
Healthcare | 1.50% | 1.83% |
#22
4
Prev: #18
|
1.6 | no change | no change |
P
S
|
235,862 | $50,295,213 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RAPT
RAPT Therapeuti...
|
Healthcare | 1.39% | 0.59% |
#23
17
Prev: #40
|
3.6 | 794,534 | 136.9% |
P
S
|
1,375,000 | $46,571,250 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TBLA
Taboola.com Ltd
|
Communication Services | 1.37% | 1.33% |
#24
Prev: #24
|
1.5 | no change | no change |
P
S
|
9,969,495 | $45,959,372 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LXRX
Lexicon Pharmac...
|
Healthcare | 1.34% | 2.06% |
#25
11
Prev: #14
|
1.5 | no change | no change |
P
S
|
38,918,903 | $44,756,738 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ZYME
Zymeworks Inc
|
Healthcare | 1.32% | — |
#26
Prev: #—
|
4.0 | 1,680,121 | no change |
NEW
|
1,680,121 | $44,237,586 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SLDB
Solid Bioscienc...
|
Healthcare | 1.29% | 1.79% |
#27
7
Prev: #20
|
1.0 | 274,500 | 3.7% |
P
S
|
7,690,405 | $43,373,884 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
WVE
WAVE Life Scien...
|
Healthcare | 1.24% | 1.06% |
#28
1
Prev: #29
|
0.5 | -1,246,322 | -33.7% |
P
S
|
2,450,000 | $41,650,000 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XENE
Xenon Pharmaceu...
|
Healthcare | 1.09% | 1.28% |
#29
4
Prev: #25
|
1.4 | no change | no change |
P
S
|
812,761 | $36,427,948 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DBVT
Dbv Technologie...
|
Healthcare | 1.06% | — |
#30
Prev: #—
|
3.9 | 1,857,362 | no change |
NEW
|
1,857,362 | $35,605,630 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ERAS
Erasca Inc
|
Healthcare | 0.97% | 0.75% |
#31
4
Prev: #35
|
1.4 | no change | no change |
P
S
|
8,757,249 | $32,576,966 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ENGN
enGene Holdings...
|
Healthcare | 0.90% | — |
#32
Prev: #—
|
3.9 | 3,336,264 | no change |
NEW
|
3,336,264 | $30,126,464 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TRVI
Trevi Therapeut...
|
Healthcare | 0.85% | 0.91% |
#33
1
Prev: #32
|
0.8 | -250,000 | -9.9% |
P
S
|
2,286,867 | $28,631,575 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SYRE
Spyre Therapeut...
|
Healthcare | 0.80% | 0.24% |
#34
25
Prev: #59
|
3.3 | 450,000 | 122.1% |
P
S
|
818,598 | $26,817,270 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MLYS
Mineralys Thera...
|
Healthcare | 0.76% | — |
#35
Prev: #—
|
3.8 | 699,999 | no change |
NEW
|
699,999 | $25,402,964 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DNLI
Denali Therapeu...
|
Healthcare | 0.69% | 0.47% |
#36
10
Prev: #46
|
3.3 | 575,000 | 70.0% |
P
S
|
1,396,513 | $23,056,430 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RELY
Remitly Global ...
|
Technology | 0.67% | 1.03% |
#37
7
Prev: #30
|
1.3 | no change | no change |
P
S
|
1,618,271 | $22,332,140 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
FULC
Fulcrum Therape...
|
Healthcare | 0.66% | — |
#38
Prev: #—
|
3.8 | 1,950,000 | no change |
NEW
|
1,950,000 | $22,054,500 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RAPP
Rapport Therape...
|
Healthcare | 0.64% | 1.22% |
#39
12
Prev: #27
|
0.3 | -345,000 | -32.7% |
P
S
|
708,469 | $21,494,949 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SLN
Silence Therape...
|
Healthcare | 0.53% | 0.59% |
#40
1
Prev: #39
|
1.2 | no change | no change |
P
S
|
2,911,438 | $17,701,543 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IHS
IHS Holding Lim...
|
Real Estate | 0.52% | 0.63% |
#41
5
Prev: #36
|
1.2 | no change | no change |
P
S
|
2,357,520 | $17,587,099 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GOSS
Gossamer Bio In...
|
Healthcare | 0.48% | 0.54% |
#42
Prev: #42
|
1.2 | no change | no change |
P
S
|
5,208,968 | $16,147,801 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
UPB
Upstream Bio In...
|
Healthcare | 0.48% | 0.58% |
#43
2
Prev: #41
|
0.2 | -200,000 | -25.4% |
P
S
|
588,450 | $15,976,418 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BCYC
Bicycle Therape...
|
Healthcare | 0.43% | 0.61% |
#44
6
Prev: #38
|
1.2 | no change | no change |
P
S
|
2,012,752 | $14,250,284 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MNPR
Monopar Therape...
|
Healthcare | 0.41% | — |
#45
Prev: #—
|
3.7 | 212,298 | no change |
NEW
|
212,298 | $13,863,059 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CGEM
Cullinan Therap...
|
Healthcare | 0.37% | 0.28% |
#46
10
Prev: #56
|
1.1 | no change | no change |
P
S
|
1,193,410 | $12,351,794 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SION
Sionna Therapeu...
|
Healthcare | 0.37% | 0.37% |
#47
1
Prev: #48
|
0.6 | -25,000 | -7.7% |
P
S
|
300,000 | $12,342,000 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IKT
Inhibikase Ther...
|
Healthcare | 0.36% | — |
#48
Prev: #—
|
3.6 | 5,850,000 | no change |
NEW
|
5,850,000 | $11,992,500 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IMAB
NovaBridge Bios...
|
Unknown | 0.36% | 0.17% |
#49
20
Prev: #69
|
3.1 | 1,834,043 | 157.3% |
P
S
|
3,000,000 | $11,940,000 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AMZN
Amazon.com Inc
|
Consumer Cyclical | 0.35% | 0.50% |
#50
6
Prev: #44
|
0.6 | -7,000 | -12.0% |
P
S
|
51,500 | $11,887,230 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-50 of 141 holdings